HALO Prostate AI, from Indica Labs, is a CE-IVD certified deep learning based screening tool designed to assist pathologists in the identification and grading of prostate cancer in core needle biopsies. The algorithm automatically analyzes all appropriate case slides and notifies pathologists of cases with suspected findings directly in their native workflow.
The algorithm reports a comprehensive set of results and markups, including cancer detection and localization, tumor size, Gleason grading, the presence of high-grade PIN and intraductal carcinoma.
Seamlessly Integrated, AI-Enhanced Workflow
- CE-IVD marked with best-in-class clinical sensitivity and specificity
- Deploy as a screening tool to support triage or as a post-diagnostic QC-check
- Results can be shared with LIS | LIMS systems from any vendor
- Deploys in your own IT environment – cloud or on-premise – so you maintain full control of the data
- Extend your image analysis capability with further integration of IHC image analysis from Indica Labs
- Non-proprietary (JPG, TIF, OME.TIFF)
- Nikon (ND2)
- 3DHistech (MRXS)
- Akoya (QPTIFF, component TIFF)
- Olympus / Evident (VSI)
- Hamamatsu (NDPI, NDPIS)
- Aperio (SVS, AFI)
- Zeiss (CZI)
- Leica (SCN, LIF)
- Ventana (BIF)
- Philips (iSyntax, i2Syntax)
- KFBIO (KFB, KFBF)
- DICOM (DCM*)
HALO Prostate AI Brochure
HALO Prostate AI offers pathologists a CE-IVD certified deep learning-based tool that can reduce turnaround times while demonstrating negative predictive values of 99% or greater in validation studies.
Novel CE-IVD Clinical Workflow for Analysis of Prostate Cancer Core Needle Biopsies
Learn more about Indica Labs’ novel CE-IVD certified deep learning clinical workflow for prostate cancer grading.
Seamless Deployment in HALO AP®
HALO Prostate AI is deployed and fully integrated into HALO AP®, the AI-powered, pathologist-driven platform for anatomic pathology workflows from Indica Labs.
HALO AP®, provides end-to-end integration to scanners and LIS | LIMS while providing built in compliance and certifications: CE-IVD, FDA 21 CFR Part 11, ISO 13485:2016, HIPAA, and GDPR.
*HALO AP® is CE-marked for in-vitro diagnostic use in Europe and the UK. HALO AP is For Research Use Only in the US and is not FDA cleared for clinical diagnostic use.
*HALO AI Prostate is CE-marked for in-vitro diagnostic use in Europe and the UK. HALO AI Prostate is For Research Use Only in the US and is not FDA cleared for clinical diagnostic use.
Press Release: Indica Labs achieves CE-IVD certification for AI-based Prostate Cancer Detection and Gleason Grading Tool
ALBUQUERQUE, NM – May 24, 2022 – Indica Labs, the leading provider of computational pathology software and services, is excited to announce a CE-IVD Mark for HALO Prostate AI, a deep learning-based screening tool designed to assist pathologists in identifying and grading prostate cancer in core needle biopsies.
Want to Learn More?
Fill out the form below to request a live demo of HALO Prostate AI or to learn more about our other clinical solutions.
You can also drop us an email at firstname.lastname@example.org